DailyDoctor Archive Specialties Get app
Back to the 24 October 2026 edition

Research · 02 of 05

Early rhythm control after ischaemic stroke with atrial fibrillation was associated with fewer recurrent strokes

Early rhythm control after a cardioembolic stroke is worth discussing with cardiology, but it should not replace anticoagulation.

Design
Nationwide claims cohort with propensity overlap weighting and landmark analysis
Population
14,355 adults in Japan with acute ischaemic stroke and atrial fibrillation
Primary outcome
Hospitalisation for recurrent ischaemic stroke or systemic embolism
Effect
HR 0.56 (95% CI 0.32 to 0.97); 5-year incidence 8.0% vs 13.8%

Using a Japanese administrative database, researchers compared patients who started antiarrhythmic drugs, ablation or cardioversion within eight weeks of an ischaemic stroke with those who did not. Few received early rhythm control.

Early rhythm control was associated with a lower risk of recurrent stroke or embolism and lower mortality. Results held across different landmark times.

Patients selected for rhythm control are likely healthier, and weighting cannot fully remove that bias. The signal is consistent with EAST-AFNET 4, which enrolled patients with recent atrial fibrillation, but a stroke-specific randomised trial is needed.

  • Five-year recurrent stroke or embolism was 8.0% with early rhythm control against 13.8% without.
  • All-cause mortality was also lower (HR 0.72).
  • Major bleeding was not significantly different.
  • The cohort was old, median age 83, so selection of fitter patients for rhythm control is likely.
  • Anticoagulation remains the main secondary prevention for cardioembolic stroke.

Why it matters

Rhythm control is rarely started after stroke; only 1.9% of this cohort received it, despite trial evidence for early rhythm control in atrial fibrillation generally.

Don't overread it

This is an observational claims analysis; the authors call it hypothesis-generating.

The statistics, in plain English

An HR of 0.56 with an interval from 0.32 to 0.97 only just excludes no effect, and the risk difference interval crosses zero. With 268 treated patients, the estimate is imprecise.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

dementiastrokeneuromuscular

Tomorrow morning, before your first patient

One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free
Daily Doctor All 27 specialties, every morning. Free.
Get the app